- CCAAT/enhancer-binding
protein alpha is a
protein encoded by the
CEBPA gene in humans. CCAAT/enhancer-binding
protein alpha is a
transcription factor...
-
neoplasms with
germline predisposition Acute myeloid leukaemia with
germline CEBPA mutation Myeloid neoplasms with
germline DDX41
mutation Myeloid neoplasms...
-
therapeutics are
currently in
clinical development. MTL-
CEBPA,
developed by MiNA Therapeutics,
targets the
CEBPA gene and is in
Phase II
trials for
liver cancer...
-
study for
their prognostic impact in AML. However, only FLT3-ITD, NPM1,
CEBPA and c-KIT are
currently included in
validated international risk stratification...
-
preclinical studies to
human clinical trials. MTL-
CEBPA:
Developed by MiNA Therapeutics, MTL-
CEBPA is the
first saRNA drug
candidate to
enter clinical...
-
neoplasms with germ line
predisposition and
organ dysfunction includes CEBPA/DDX41/RUNX1 disorders, GATA2
deficiency and SAMD9/9L syndromes. The goals...
-
mutations have been
implicated in
cancer (e.g.,
mutations in
genes p53, ATM,
CEBPA, and PPARgamma).
Marfan syndrome is
caused by
mutations in the FBN1 gene...
- CA, van
Putten WL, Valk PJ,
Delwel R (Mar 2009). "Double
CEBPA mutations, but not
single CEBPA mutations,
define a
subgroup of
acute myeloid leukemia with...
-
kinase 2 has been
shown to
interact with: BRCA1, CDK2AP1, CDKN1B CDKN3,
CEBPA,
Cyclin A1,
Cyclin E1, Flap structure-specific
endonuclease 1, ORC1L, P21...
- Meshinchi, S (25 June 2009). "Prevalence and
prognostic implications of
CEBPA mutations in
pediatric acute myeloid leukemia (AML): a
report from the Children's...
